Invesaro

Stocks Comparison

Enigmatig vs Pharma-Bio Serv: revenue, profit, margins and growth compared

Enigmatig brought in $4.5M of revenue in fiscal 2025, Pharma-Bio Serv $9M in fiscal 2025. Revenue changed by +12.2% at Enigmatig and -5.3% at Pharma-Bio Serv on the year before, so Enigmatig grew faster. Enigmatig kept 12.6% of its revenue as net profit, Pharma-Bio Serv -1.1%. Free cash flow was -$2M at Enigmatig and -$221.5K at Pharma-Bio Serv.

Side by side, latest fiscal year

EGGPBSV
Fiscal year endedFY2025 (September 30, 2025)FY2025 (October 31, 2025)
Revenue$4.5M$9M
Revenue growth+12.2%-5.3%
Net income$559.7K-$100.5K
Net margin12.6%-1.1%
Free cash flow-$2M-$221.5K
Free cash flow margin-44.1%-2.5%
Earnings per share (diluted)$0.02-$0.00
Cash$13.2M$3.4M
Debtn/an/a
Price to earningsn/an/a
Market valuen/a$8M
Dividend yieldn/an/a
Rank by revenue in sector#528 of 587 · Industrials#508 of 587 · Industrials

Over the years

Revenue
EGG FY2023: $4.6MEGG FY2025: $4MEGG FY2025: $4.5MPBSV FY2018: $17.8MPBSV FY2019: $19.5MPBSV FY2020: $21.6MPBSV FY2021: $20.1MPBSV FY2022: $19.4MPBSV FY2023: $17MPBSV FY2024: $9.5MPBSV FY2025: $9MFY18FY19FY20FY21FY22FY23FY24FY25
EGG $4.5MPBSV $9M
Net income
EGG FY2023: $1.1MEGG FY2025: $821.2KEGG FY2025: $559.7KPBSV FY2018: $1.3MPBSV FY2019: $2.1MPBSV FY2020: $2.1MPBSV FY2021: -$2.1MPBSV FY2022: $1MPBSV FY2023: $1.3MPBSV FY2024: -$777.6KPBSV FY2025: -$100.5KFY18FY19FY20FY21FY22FY23FY24FY25
EGG $559.7KPBSV -$100.5K
Net margin
EGG FY2023: 24.6%EGG FY2025: 20.7%EGG FY2025: 12.6%PBSV FY2018: 7.2%PBSV FY2019: 10.7%PBSV FY2020: 9.5%PBSV FY2021: -10.4%PBSV FY2022: 5.2%PBSV FY2023: 7.7%PBSV FY2024: -8.2%PBSV FY2025: -1.1%FY18FY19FY20FY21FY22FY23FY24FY25
EGG 12.6%PBSV -1.1%
Revenue growth
EGG FY2025: -13.9%EGG FY2025: +12.2%PBSV FY2019: +9.6%PBSV FY2020: +10.5%PBSV FY2021: -6.7%PBSV FY2022: -3.6%PBSV FY2023: -12.5%PBSV FY2024: -44.0%PBSV FY2025: -5.3%FY19FY20FY21FY22FY23FY24FY25
EGG +12.2%PBSV -5.3%
Free cash flow
EGG FY2023: -$62.8KEGG FY2025: -$606.1KEGG FY2025: -$2MPBSV FY2018: $3.6MPBSV FY2019: -$2.3MPBSV FY2020: $1.5MPBSV FY2021: $794KPBSV FY2022: $573.2KPBSV FY2023: $1.9MPBSV FY2024: -$726.4KPBSV FY2025: -$221.5KFY18FY19FY20FY21FY22FY23FY24FY25
EGG -$2MPBSV -$221.5K

Fiscal years as each company reports them; the two may end in different months.

Questions about Enigmatig and Pharma-Bio Serv

Which is bigger by revenue, Enigmatig or Pharma-Bio Serv?

Pharma-Bio Serv is bigger by revenue: $9M in fiscal 2025, against $4.5M for Enigmatig in fiscal 2025.

Which keeps more of its revenue as profit, Enigmatig or Pharma-Bio Serv?

Enigmatig had a net margin of 12.6% in fiscal 2025; Pharma-Bio Serv had -1.1% in fiscal 2025.

Which grew revenue faster, Enigmatig or Pharma-Bio Serv?

In their latest fiscal years revenue changed by +12.2% at Enigmatig and -5.3% at Pharma-Bio Serv.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies